GlobeNews Wire

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

September 02, 2025 21:33 ET  | Source: Mineralys Therapeutics, Inc. RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics,…

10 months ago

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from…

10 months ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 02, 2025 17:00 ET  | Source: ZENTALIS PHARMACEUTICALS SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc.…

10 months ago

How Sparkvia AI Website Tool Proves Real AI Utility on XRP SPARK Public Sale is Open for Early Investors

VALLETTA, Malta, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sparkvia AI has officially opened the public sale of its utility token,…

10 months ago

CEA Industries (BNC) Appoints Seasoned Global Investments Leader, Dr. Russell Read, as Non-Executive Director

New York, Sept. 02, 2025 (GLOBE NEWSWIRE) -- CEA Industries Inc. (Nasdaq: BNC), (“BNC” or “the Company”), a growth-oriented company focused…

10 months ago

Cycurion to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a premier cybersecurity and…

10 months ago

FIRST PATIENT DOSED IN CITRYLLS PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS

Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis…

10 months ago

CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML

New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla VenturesCHARM’s AI-designed menin inhibitor…

10 months ago

Coloplast A/S – Announcement no. 07/2025 – Coloplast announces new financial ambition towards 2030

In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue…

10 months ago

Zhejiang-based GNMI Expands Overseas: Hangzhou Becomes a New Starting Point for the China-German Industrial Synergies

Hangzhou, China, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Against the backdrop of West Lake, where the reflections of water meet…

10 months ago